Exelixis | EXEL - Ordinary Share Capital


Exelixis reported $244.68M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Agios Pharmaceuticals USD 59.6M 264K Jun/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Amgen USD 541M 0 Sep/2026
AstraZeneca USD 1.55B 28K Sep/2026
Bayer EUR 982.42M 0 Sep/2026
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Cytokinetics USD 138.76M 14.33M Jun/2026
Eisai JPY 282.46M 0 Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 244.68M 4.21M Sep/2026
Genmab DKK 61.44M 181K Jun/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 166.41M 773K Sep/2026
MacroGenics USD 63.65M 86K Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novartis USD 1.89B 12.09M Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
Puma Biotechnology USD 5K 0 Jun/2024
Sanofi EUR 1.2B 2.15M Jun/2026
Takeda JPY 1.58B 460K Jun/2026
Ultragenyx Pharmaceutical USD 98.6M 300K Jun/2026
Xencor USD 74.33M 265K Jun/2026